<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270025" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39420874</article-id><article-id pub-id-type="pmc">PMC11483557</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70025</article-id><article-id pub-id-type="publisher-id">DEO270025</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Propofol&#x02010;alone sedative efficacy in observational biliopancreatic endoscopic ultrasound</article-title><alt-title alt-title-type="left-running-head">KATO <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="deo270025-cr-0001" contrib-type="author"><name><surname>Kato</surname><given-names>Hisaki</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-9724-9824</contrib-id><xref rid="deo270025-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270025-cr-0002" contrib-type="author"><name><surname>Kawasaki</surname><given-names>Yuki</given-names></name><xref rid="deo270025-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270025-cr-0003" contrib-type="author"><name><surname>Sumi</surname><given-names>Kazuya</given-names></name><xref rid="deo270025-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270025-cr-0004" contrib-type="author" corresp="yes"><name><surname>Shibata</surname><given-names>Yuki</given-names></name><xref rid="deo270025-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>kawasakiyuki1219@gmail.com</email></address></contrib><contrib id="deo270025-cr-0005" contrib-type="author"><name><surname>Nomura</surname><given-names>Norihiro</given-names></name><xref rid="deo270025-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270025-cr-0006" contrib-type="author"><name><surname>Ushio</surname><given-names>Jun</given-names></name><xref rid="deo270025-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270025-cr-0007" contrib-type="author"><name><surname>Eguchi</surname><given-names>Junichi</given-names></name><xref rid="deo270025-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270025-cr-0008" contrib-type="author"><name><surname>Ito</surname><given-names>Takayoshi</given-names></name><xref rid="deo270025-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270025-cr-0009" contrib-type="author"><name><surname>Inoue</surname><given-names>Haruhiro</given-names></name><xref rid="deo270025-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="deo270025-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Digestive Diseases Center</named-content>
<institution>Showa University Koto Toyosu Hospital</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Yuki Kawasaki, Department of Digestive Diseases Center, Showa University Koto Toyosu Hospital, 5&#x02010;1&#x02010;38 Toyosu, Koto&#x02010;ku, Tokyo, Japan.<break/> Email: <email>kawasakiyuki1219@gmail.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="66">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70025</elocation-id><history>
<date date-type="rev-recd"><day>19</day><month>9</month><year>2024</year></date>
<date date-type="received"><day>09</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>30</day><month>9</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70025.pdf"/><abstract><title>Abstract</title><sec id="deo270025-sec-0010"><title>Objectives</title><p>Appropriate sedative and analgesic selection is essential to reduce patient discomfort and body movement to safely conduct endoscopic ultrasonography (EUS). However, few cases have examined sedation with propofol in EUS, and few studies the need for combined analgesia. In this study, we retrospectively evaluated the usefulness and safety of propofol without analgesics for sedation in biliopancreatic observational EUS.</p></sec><sec id="deo270025-sec-0020"><title>Methods</title><p>This single&#x02010;center retrospective study included 516 observational biliopancreatic EUS procedures using propofol alone performed between April 2021 and March 2023. The primary and secondary endpoints were the observational biliopancreatic EUS results obtained with propofol alone and adverse event occurrence, respectively.</p></sec><sec id="deo270025-sec-0030"><title>Results</title><p>The median examination time and total propofol dose were 22 (range: 10&#x02013;67) min and 186.5 (range: 50&#x02013;501) mg, respectively. The median starting Richmond Agitation&#x02010;Sedation Scale and Visual Analog Scale scores were &#x02212;5 (range: &#x02212;5&#x02013;1) and 0 (range: 0&#x02013;10), respectively. The median recovery time was 22 (range: 5&#x02013;80) min. Adverse events occurred in 60 (11.6%) patients. Trainee&#x02010;performed examination (odds ratio [OR] 3.52, 95% confidence interval [CI]: 1.63&#x02013;7.60, <italic toggle="yes">p</italic> = 0.0014) and examination length (&#x0003e;22 min; OR 1.67, 95% CI: 0.95&#x02013;2.92, <italic toggle="yes">p</italic> = 0.07) were risk factors for adverse events.</p><p>High body mass index (OR 1.87, 95% CI: 1.10&#x02013;3.16, <italic toggle="yes">p</italic> = 0.02) and extended examination time (OR 4.23, 95% CI: 2.08&#x02013;8. 57, <italic toggle="yes">p</italic> &#x0003c; 0.001) were risk factors for delayed recovery.</p></sec><sec id="deo270025-sec-0040"><title>Conclusions</title><p>During observational biliopancreatic EUS, propofol is useful as a single sedative and offers high patient satisfaction and relative safety.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270025-kwd-0001">analgesics</kwd><kwd id="deo270025-kwd-0002">endoscopic ultrasonography</kwd><kwd id="deo270025-kwd-0003">propofol</kwd><kwd id="deo270025-kwd-0004">sedative</kwd><kwd id="deo270025-kwd-0005">sedative efficacy</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="7"/><page-count count="9"/><word-count count="4614"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270025-sec-0050"><title>INTRODUCTION</title><p>Sedation endoscopy is preferred for its focus on safety and high patient satisfaction. It has been reported to be beneficial for both patients and endoscopists in improving the quality of examinations.<xref rid="deo270025-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo270025-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>In recent years, endoscopic ultrasonography (EUS) has become increasingly important in the rising incidence of biliopancreatic diseases and early diagnosis of biliopancreatic cancer because of its high visualization ability.<xref rid="deo270025-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>Endoscopic retrograde cholangiopancreatography (ERCP) and EUS have a larger scope diameter and longer examination time compared to upper gastrointestinal endoscopy. Therefore, it is crucial to choose proper sedatives and analgesics to minimize patient discomfort and movement for safe ERCP and EUS procedures.</p><p>Common hypnotic sedatives include benzodiazepines, dexmedetomidine hydrochloride, pethidine hydrochloride, and fentanyl. Pentazocine acts as an antagonistic analgesic. Propofol is an ultrashort&#x02010;acting sedative given intravenously, which sedates patients rapidly and effectively. Unlike opioids, it lacks analgesic properties but has a shorter elimination half&#x02010;life and quicker arousal time. Additionally, it is associated with fewer adverse events like nausea and vomiting.</p><p>Reportedly, propofol usage in endoscopy results in shorter recovery times, fewer interruptions during long procedures, and increased satisfaction among physicians, nurses, and patients.<xref rid="deo270025-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>A study on sedation related to ERCP revealed that a randomized controlled trial comparing sedatives alone and sedatives plus analgesics groups reported reduced pain and higher satisfaction levels among patients and endoscopists in the combination group.<xref rid="deo270025-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Additionally, a meta&#x02010;analysis of randomized controlled trials comparing propofol use in ERCP and EUS with conventional sedatives showed no significant differences in the incidence of hypotension, hypoxemia, or procedure time, but did reveal a significantly quicker recovery time.<xref rid="deo270025-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="deo270025-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Yusoff et&#x000a0;al. also reported that during upper gastrointestinal EUS examinations using propofol, all patients preferred the same sedation for their subsequent examination.<xref rid="deo270025-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>Various comparative studies have been conducted on sedation and analgesia in ERCP. However, none have compared the use of sedatives alone with the use of both sedatives and analgesics in EUS. Additionally, the use of sedation with propofol during EUS has only been studied in a limited number of cases, with few studies looking into the necessity of combined analgesia.<xref rid="deo270025-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="deo270025-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>In this study, we evaluated the usefulness and safety of propofol sedation without analgesics during biliopancreatic observational EUS.</p></sec><sec id="deo270025-sec-0060"><title>MATERIALS AND METHODS</title><sec id="deo270025-sec-0070"><title>Patients</title><p>This is a single&#x02010;center retrospective analysis of patients sedated with propofol only and without analgesics during biliopancreatic EUS observation. We included observational biliopancreatic EUS performed between April 2021 and March 2023. The selection process is illustrated in Figure&#x000a0;<xref rid="deo270025-fig-0001" ref-type="fig">1</xref>. During the study period, 536 patients underwent biliopancreatic EUS observation. Of these, 20 patients (3.7%) were excluded (one patient using midazolam, one patient with analgesia, one patient requesting no sedation, and 17 patients who underwent simultaneous ERCP). We retrospectively examined 516 patients (96.2%).</p><fig position="float" fig-type="FIGURE" id="deo270025-fig-0001"><label>FIGURE 1</label><caption><p>The selection of patients who underwent observational biliopancreatic endoscopic ultrasonography (EUS).</p></caption><graphic xlink:href="DEO2-5-e70025-g001" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="deo270025-sec-0080"><title>Observational EUS</title><p>Observational biliopancreatic EUS was performed using an echoendoscope (GF&#x02010;UE290 and GF&#x02010;UCT260; Olympus Medical Systems) and an endoscopic ultrasound observation device (EU&#x02010;ME2; Olympus Medical Systems).</p><p>All patients were checked for medical history, risk assessment by comorbidity (cardiac disease [ischemia and arrhythmia], chronic obstructive pulmonary disease [COPD], and sleep apnea syndrome [SAS]), medications, and allergies. Pre&#x02010;sedation evaluation was performed using a checklist.</p><p>The trainee and/or trainer performed observation EUS, and all patients were sedated with propofol alone. All patients were anesthetized by the EUS physician or trainer. Even when the trainee performed EUS, it was supervised by an endoscopist (trainer) with at least 5 years of EUS experience and at least 100 cases of EUS&#x02010;guided tissue acquisition (EUS&#x02010;TA), who also made the final diagnosis.</p><p>Sedation was initiated using propofol at a dose of 0.5&#x02013;1.0 mg/kg for induction, followed by a continuous maintenance dose of 3 mg/kg/h administered via a syringe pump.</p><p>Additional propofol in 10&#x02013;20&#x02010;mg increments was given as needed during movement or poor sedation, with repeat doses administered until adequate anesthesia induction was achieved. Bolus and sustained doses of propofol at induction, as well as reasons for any extra bolus (such as body movement or pain), were recorded during the examination. Vital signs were monitored every 5 min for all patients during the procedure, with monitoring every 10 min in the recovery room afterward. Symptoms such as abdominal pain, nausea, and recovery time were also noted. Patient satisfaction was assessed pre&#x02010;discharge using a visual analog scale (VAS).</p><p>All patient records were collected and documented in a checklist format by the nurses at the endoscopy center.</p></sec><sec id="deo270025-sec-0090"><title>Outcome measures</title><p>The primary endpoint of the study was the observational biliopancreatic EUS results using propofol alone. This included the patient's distress levels, adverse events, and recovery time from completion of examination to release from rest in outpatients.</p><p>The secondary endpoints were adverse event factors, propofol dose, and examination time.</p></sec><sec id="deo270025-sec-0100"><title>Definition</title><p>The Richmond Agitation&#x02010;Sedation Scale (RASS) score was expressed as positive and negative for arousal and sedation, respectively, with +4 for dangerously excited, 0 for calm, and &#x02212;5 for unarousable.<xref rid="deo270025-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo270025-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>Patient satisfaction was measured using the VAS, with 0 indicating comfort and 10 indicating discomfort.</p><p>Respiratory depression was defined as pulse oxygen saturation (SpO<sub>2</sub>) &#x0003c;90%, necessitating oxygen administration.</p><p>Hypotension was defined as systolic blood pressure &#x0003c;90 mmHg and bradycardia as heart rate &#x0003c;50 bpm.</p><p>The anesthesia recovery score determined when a patient could be released from rest, assessed by levels of consciousness, motor function, respiration, circulation, and SpO<sub>2</sub> (Table&#x000a0;<xref rid="deo270025-tbl-0001" ref-type="table">1</xref>).<xref rid="deo270025-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo270025-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo270025-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> An anesthesia recovery score of 8 or higher allowed rest release.</p><table-wrap position="float" id="deo270025-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Anesthesia recovery score.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Criteria</th><th align="left" rowspan="1" colspan="1">Score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Activity</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Movement, spontaneously or on command</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Weak movement, spontaneously or on command</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">No movement</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiration</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Coughs on command or cries</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Maintains airway without support</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Airway maintenance required</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000b1;20 mmHg of pre&#x02010;anesthetic level</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000b1;20&#x02013;50 mmHg of pre&#x02010;anesthetic level</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;50 mmHg of pre&#x02010;anesthetic level</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Consciousness</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Wakefulness or easily awakened when called</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Defensive reflexes to stimuli</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">No response or absence of defensive reflexes</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">O<sub>2</sub> saturation</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Saturation &#x02265;92% or &#x02265; pre&#x02010;anesthetic value in room air</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Saturation &#x02265;92% or &#x02265; pre&#x02010;anesthetic value with</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">supplemental O<sub>2</sub>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Saturation &#x02264;92%</td><td align="left" rowspan="1" colspan="1">0</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The time from the end of the examination until the patient was released from rest and could return home was the recovery time, with delayed recovery time being at least 30 min.</p><p>Adverse events were defined based on the lexicon of endoscopic adverse events as outlined by the American Society for Gastrointestinal Endoscopy.<xref rid="deo270025-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>Gastroenterologists who were able to complete routine abdominal ultrasonography and upper and lower endoscopy independently were assigned as trainees to begin training. A trainer&#x000a0;must have at least 5 years of EUS experience and at least 100 cases of EUS&#x02010;TA at a specialized institution.</p></sec><sec id="deo270025-sec-0110"><title>Statistical analysis</title><p>Continuous variables, including age and length of the procedure, were presented as medians and ranges, and categorical variables as proportions. The univariate analyses were performed using the &#x003c7;<sup>2</sup> or Fisher's exact test for categorical variables and the Mann&#x02013;Whitney U&#x02010;test for continuous variables. Statistical significance was set at <italic toggle="yes">p</italic> &#x0003c; 0.05. Multivariate analysis was performed using logistic regression modeling, and factors with a univariate <italic toggle="yes">p</italic>&#x02010;value of &#x0003c;0.05 were entered into the multivariate model. All data analyses were performed using the JMP Statistics for Windows (version 17.0; SAS Institute Japan Corp.).</p></sec><sec id="deo270025-sec-0120"><title>Ethics approval</title><p>The Showa University Koto Toyosu Hospital Review Board (No. 2023&#x02010;229&#x02010;B) approved this study. This study conformed to the provisions of the Declaration of Helsinki (revised in Fortaleza, Brazil, October 2013).</p></sec></sec><sec id="deo270025-sec-0130"><title>RESULTS</title><sec id="deo270025-sec-0140"><title>Patient background</title><p>The clinical characteristics of the 516 patients (254 [49.2%] males and 262 [50.8%] females) are presented in Table&#x000a0;<xref rid="deo270025-tbl-0002" ref-type="table">2</xref>. The patients&#x02019; median age and body mass index (BMI) were 65 (range: 25&#x02013;94) years and 22.4 (range: 14.0&#x02013;38.1) kg/m<sup>2</sup>, respectively. Outpatient procedures were performed in 437 patients (84.7%) and inpatient procedures in 79 patients (15.3%). In total, 113 (21.9%) patients underwent esophagogastroduodenoscopy (EGD) simultaneously with observational biliopancreatic EUS. The radial type was used in 510 cases (98.8%) and the convex type in six cases (1.2%). Trainees, alongside their trainers, performed 343 (66.5%) cases, while 173 (33.5%) were performed by trainers alone. Of these, 43 patients (8.3%) had comorbidities (one [0.2%] with SAS, three [0.6%] with COPD, and 39 [7.5%] with cardiac disease).</p><table-wrap position="float" id="deo270025-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Clinical characteristics&#x000a0;of the study population.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> = 516</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median age, years (range)<xref rid="deo270025-tbl2-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">65&#x000a0;(25&#x02013;94)</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">254&#x000a0;(49.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median&#x000a0;height, m (range)</td><td align="char" rowspan="1" colspan="1">1.61&#x000a0;(1.35&#x02013;1.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median&#x000a0;body weight,&#x000a0;kg&#x000a0;(range)</td><td align="char" rowspan="1" colspan="1">57.7&#x000a0;(34.2&#x02013;131.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median&#x000a0;BMI,&#x000a0;kg/m<sup>2</sup>&#x000a0;(range)</td><td align="char" rowspan="1" colspan="1">22.4&#x000a0;(14.0&#x02013;38.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">437(84.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Simultaneous performance of&#x000a0;EGD, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">113&#x000a0;(21.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Scope&#x000a0;type&#x000a0;of EUS, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Radial</td><td align="char" rowspan="1" colspan="1">510&#x000a0;(98.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Convex</td><td align="char" rowspan="1" colspan="1">6&#x000a0;(1.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">EUS provider, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Trainee + trainer</td><td align="char" rowspan="1" colspan="1">343&#x000a0;(66.5)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Trainer</td><td align="char" rowspan="1" colspan="1">173&#x000a0;(33.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">43&#x000a0;(8.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">SAS</td><td align="char" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">COPD</td><td align="char" rowspan="1" colspan="1">3&#x000a0;(0.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac disease (ischemia and arrhythmia)</td><td align="char" rowspan="1" colspan="1">39&#x000a0;(7.5)</td></tr></tbody></table><table-wrap-foot><fn id="deo270025-tbl2-note-0002"><p>Abbreviations: BMI, body mass index; COPD,&#x000a0;chronic obstructive pulmonary disease; EGDS,&#x000a0;esophagogastroduodenoscopy; EUS, endoscopic&#x000a0;ultrasonography; SAS, sleep apnea syndrome.</p></fn><fn id="deo270025-tbl2-note-0001"><label>
<sup>a</sup>
</label><p>Age at which EUS was performed.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270025-sec-0150"><title>Sedation results of observational biliopancreatic EUS</title><p>The median examination time was 22 (range: 10&#x02013;67) min. The median total propofol dose was 186.5 (range: 50&#x02013;501) mg. The median starting RASS score was &#x02212;5 (range: &#x02212;5&#x02013;1), and the median VAS score was 0 (range: 0&#x02013;10). The median recovery time was 22 (range: 5&#x02013;80) min. Adverse events were observed in 60 patients (11.6%), including respiratory depression in 25 (4.8%), hypotension in 15 (2.9%), bradycardia in six (1.2%), disinhibition in 12 (2.3%), extravascular propofol leakage in one (0.2%), and acute pancreatitis in one patient (0.2%; Table&#x000a0;<xref rid="deo270025-tbl-0003" ref-type="table">3</xref>). All the adverse events were of mild grade. No re&#x02010;sedation was observed after the patient returned home. All the adverse events overlapped with respiratory depression: nine cases of hypotension, one case of bradycardia, and four cases of de&#x02010;suppression.</p><table-wrap position="float" id="deo270025-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Endoscopic ultrasonography results for the study&#x000a0;population.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> = 516</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median&#x000a0;examination&#x000a0;time,&#x000a0;min&#x000a0;(range)</td><td align="char" rowspan="1" colspan="1">22&#x000a0;(10&#x02013;67)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median total propofol dose,&#x000a0;mg&#x000a0;(range)</td><td align="char" rowspan="1" colspan="1">186.5&#x000a0;(50&#x02013;501)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median starting RASS,&#x000a0;points&#x000a0;(range)</td><td align="char" rowspan="1" colspan="1">&#x02212;5&#x000a0;(&#x02212;5&#x02013;1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median&#x000a0;VAS,&#x000a0;points&#x000a0;(range)</td><td align="char" rowspan="1" colspan="1">0&#x000a0;(0&#x02013;10)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median&#x000a0;time to&#x000a0;awaken,&#x000a0;min&#x000a0;(range)</td><td align="char" rowspan="1" colspan="1">22&#x000a0;(5&#x02013;80)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hypoxia</td><td align="char" rowspan="1" colspan="1">25&#x000a0;(4.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hypotension</td><td align="char" rowspan="1" colspan="1">15&#x000a0;(2.9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Bradycardia</td><td align="char" rowspan="1" colspan="1">6&#x000a0;(1.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Disinhibition</td><td align="char" rowspan="1" colspan="1">12&#x000a0;(2.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Propofol&#x000a0;leakage</td><td align="char" rowspan="1" colspan="1">1&#x000a0;(0.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Acute pancreatitis</td><td align="char" rowspan="1" colspan="1">1&#x000a0;(0.2)</td></tr></tbody></table><table-wrap-foot><fn id="deo270025-tbl3-note-0001"><p>Abbreviations: RASS,&#x000a0;Richmond agitation&#x02010;sedation scale; VAS, visual analog scale.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270025-sec-0160"><title>Clinical characteristics and EUS results of&#x000a0;adverse events</title><p>Adverse event factors analyzed were age, sex, BMI, simultaneous performance of EGD, EUS provider (performed by a trainee), comorbidities (SAS, COPD, and cardiac disease), examination time, and total propofol dosage. The risk of adverse events was significantly associated with three factors: trainee&#x02010;performed tests (<italic toggle="yes">p</italic> = 0.0007), COPD comorbidities (<italic toggle="yes">p</italic> &#x0003c; 0.001), and high propofol dosage (<italic toggle="yes">p</italic> = 0.04; Table&#x000a0;<xref rid="deo270025-tbl-0004" ref-type="table">4</xref>). In addition, univariate and multivariate analyses were performed to examine factors contributing to adverse events with respect to age (&#x0003e;65 years, &#x02264;65 years), sex, BMI (&#x0003e;25 kg/m<sup>2</sup>, &#x02264;25 kg/m<sup>2</sup>), whether EGD was performed simultaneously, who performed the EUS (Trainee and Trainer or Trainer alone), presence of comorbidity, examination time (&#x0003e;22 min, &#x02264;22 min), and total propofol dosage (&#x02265;180 mg, &#x0003c;180 mg; Table&#x000a0;<xref rid="deo270025-tbl-0005" ref-type="table">5</xref>). The groups were divided based on the median age, examination time, and propofol dose. In the univariate analysis, the examination performed by the trainee (odds ratio [OR] 3.52, (95% confidence interval [CI]: 1.63&#x02013;7.60, <italic toggle="yes">p</italic> = 0.0014) was considered the risk factor for adverse events.</p><table-wrap position="float" id="deo270025-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Clinical characteristics and endoscopic ultrasonography (EUS) results of&#x000a0;adverse events.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">
<p>Total</p>
<p>
<italic toggle="yes">n</italic> = 516</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Without&#x000a0;adverse events</p>
<p>
<italic toggle="yes">n</italic> = 457</p>
</th><th align="left" rowspan="1" colspan="1">
<p>With adverse events</p>
<p>
<italic toggle="yes">n</italic> = 59</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median age, years (range)</td><td align="char" rowspan="1" colspan="1">65&#x000a0;(25&#x02013;94)</td><td align="char" rowspan="1" colspan="1">65&#x000a0;(25&#x02013;94)</td><td align="char" rowspan="1" colspan="1">65&#x000a0;(31&#x02013;92)</td><td align="char" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">254&#x000a0;(49.2)</td><td align="char" rowspan="1" colspan="1">227&#x000a0;(49.7)</td><td align="char" rowspan="1" colspan="1">27&#x000a0;(45.8)</td><td align="char" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Median&#x000a0;BMI,&#x000a0;kg/m<sup>2</sup>&#x000a0;(range)</td><td align="char" rowspan="1" colspan="1">22.4 (14.0&#x02013;38.1)</td><td align="char" rowspan="1" colspan="1">22.4 (14.0&#x02013;38.1)</td><td align="char" rowspan="1" colspan="1">22.4&#x000a0;(14.2&#x02013;30.8)</td><td align="char" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Simultaneous performance of&#x000a0;EGD, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">113&#x000a0;(21.9)</td><td align="char" rowspan="1" colspan="1">103&#x000a0;(22.5)</td><td align="char" rowspan="1" colspan="1">10&#x000a0;(16.9)</td><td align="char" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">EUS provider, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Trainee + trainer</td><td align="char" rowspan="1" colspan="1">343&#x000a0;(66.5)</td><td align="char" rowspan="1" colspan="1">293&#x000a0;(64.1)</td><td align="char" rowspan="1" colspan="1">50&#x000a0;(84.7)</td><td align="char" rowspan="1" colspan="1">0.0007</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">43&#x000a0;(8.3)</td><td align="char" rowspan="1" colspan="1">35&#x000a0;(7.6)</td><td align="char" rowspan="1" colspan="1">8&#x000a0;(13.6)</td><td align="char" rowspan="1" colspan="1">0.11</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">SAS</td><td align="char" rowspan="1" colspan="1">1 (0.2)</td><td align="char" rowspan="1" colspan="1">1&#x000a0;(0.2)</td><td align="char" rowspan="1" colspan="1">0&#x000a0;(0)</td><td align="char" rowspan="1" colspan="1">0.72</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">COPD</td><td align="char" rowspan="1" colspan="1">3&#x000a0;(0.6)</td><td align="char" rowspan="1" colspan="1">1&#x000a0;(0.2)</td><td align="char" rowspan="1" colspan="1">2&#x000a0;(3.4)</td><td align="char" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cardiac disease</td><td align="char" rowspan="1" colspan="1">39&#x000a0;(7.5)</td><td align="char" rowspan="1" colspan="1">33&#x000a0;(7.2)</td><td align="char" rowspan="1" colspan="1">6&#x000a0;(10.2)</td><td align="char" rowspan="1" colspan="1">0.3951</td></tr><tr><td align="left" rowspan="1" colspan="1">Median&#x000a0;examination&#x000a0;time,&#x000a0;min (range)</td><td align="char" rowspan="1" colspan="1">22&#x000a0;(10&#x02013;67)</td><td align="char" rowspan="1" colspan="1">21&#x000a0;(10&#x02013;67)</td><td align="char" rowspan="1" colspan="1">25&#x000a0;(10&#x02013;53)</td><td align="char" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Median total propofol dose,&#x000a0;mg (range)</td><td align="char" rowspan="1" colspan="1">186.5&#x000a0;(50&#x02013;501)</td><td align="char" rowspan="1" colspan="1">180&#x000a0;(50&#x02013;501)</td><td align="char" rowspan="1" colspan="1">210&#x000a0;(50&#x02013;490)</td><td align="char" rowspan="1" colspan="1">0.04</td></tr></tbody></table><table-wrap-foot><fn id="deo270025-tbl4-note-0001"><p>Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; EGDS, esophagogastroduodenoscopy; EUS, endoscopic ultrasonography;&#x000a0;SAS, sleep apnea syndrome.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270025-tbl-0005" content-type="TABLE"><label>TABLE 5</label><caption><p>Factors affecting&#x000a0;the&#x000a0;risk of adverse events&#x000a0;during observational&#x000a0;endoscopic ultrasonography.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">
<bold>Univariate analysis</bold>
</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">
<bold>Multivariate analysis</bold>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">
<bold>Variable</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic>
</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Adverse event risk&#x000a0;(%)</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>OR</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">p</italic>&#x02010;value</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>OR</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">p</italic>&#x02010;value</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="char" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003c;65</td><td align="left" rowspan="1" colspan="1">250</td><td align="char" rowspan="1" colspan="1">11.2&#x000a0;(28/250)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x02265;65</td><td align="left" rowspan="1" colspan="1">266</td><td align="char" rowspan="1" colspan="1">11.7&#x000a0;(31/266)</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">0.64&#x02013;1.91</td><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="char" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">254</td><td align="char" rowspan="1" colspan="1">10.6&#x000a0;(27/254)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">262</td><td align="char" rowspan="1" colspan="1">12.2&#x000a0;(32/262)</td><td align="left" rowspan="1" colspan="1">1.13</td><td align="left" rowspan="1" colspan="1">0.65&#x02013;1.95</td><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="char" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003c;25</td><td align="left" rowspan="1" colspan="1">404</td><td align="char" rowspan="1" colspan="1">10.4&#x000a0;(42/404)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x02265;25</td><td align="left" rowspan="1" colspan="1">112</td><td align="char" rowspan="1" colspan="1">15.2 (17/112)</td><td align="left" rowspan="1" colspan="1">1.42</td><td align="left" rowspan="1" colspan="1">0.76&#x02013;2.63</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Simultaneous performance of&#x000a0;EGD</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="char" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">113</td><td align="char" rowspan="1" colspan="1">8.8 (10/113)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">403</td><td align="char" rowspan="1" colspan="1">12.2&#x000a0;(49/403)</td><td align="left" rowspan="1" colspan="1">1.39</td><td align="left" rowspan="1" colspan="1">0.68&#x02013;2.85</td><td align="left" rowspan="1" colspan="1">0.36</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Provider&#x000a0;of&#x000a0;EUS</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="char" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Trainer alone</td><td align="left" rowspan="1" colspan="1">173</td><td align="char" rowspan="1" colspan="1">5.2 (9/173)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Trainer + trainee</td><td align="left" rowspan="1" colspan="1">343</td><td align="char" rowspan="1" colspan="1">14.6&#x000a0;(50/343)&#x000a0;</td><td align="left" rowspan="1" colspan="1">3.52</td><td align="left" rowspan="1" colspan="1">1.63&#x02013;7.60</td><td align="left" rowspan="1" colspan="1">0.0014</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="char" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">473</td><td align="char" rowspan="1" colspan="1">10.8 (51/473)&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">43</td><td align="char" rowspan="1" colspan="1">18.6&#x000a0;(8/43)</td><td align="left" rowspan="1" colspan="1">1.93</td><td align="left" rowspan="1" colspan="1">0.85&#x02013;4.40</td><td align="left" rowspan="1" colspan="1">0.12</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Examination time (min)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="char" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003c;22</td><td align="left" rowspan="1" colspan="1">253</td><td align="char" rowspan="1" colspan="1">8.7&#x000a0;(22/253)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x02265;22</td><td align="left" rowspan="1" colspan="1">263</td><td align="char" rowspan="1" colspan="1">14.1&#x000a0;(37/263)</td><td align="left" rowspan="1" colspan="1">1.67</td><td align="left" rowspan="1" colspan="1">0.95&#x02013;2.92</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Total propofol dose (mg)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="char" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003e;180</td><td align="left" rowspan="1" colspan="1">262</td><td align="char" rowspan="1" colspan="1">13.7&#x000a0;(36/262)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x02264;180</td><td align="left" rowspan="1" colspan="1">254</td><td align="char" rowspan="1" colspan="1">9.1&#x000a0;(23/254)</td><td align="left" rowspan="1" colspan="1">1.57</td><td align="left" rowspan="1" colspan="1">0.88&#x02013;2.78</td><td align="left" rowspan="1" colspan="1">0.12</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr></tbody></table><table-wrap-foot><fn id="deo270025-tbl5-note-0001"><p>Abbreviations: BMI, body mass index; EGDS, esophagogastroduodenoscopy; EUS, endoscopic ultrasonography.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270025-sec-0170"><title>Factors affecting delayed recovery time in observational EUS</title><p>Recovery time was considered only in outpatients based on whether the patient could return home.</p><p>Factors that delayed recovery time included age, sex, BMI, simultaneous EGD, EUS provider (performed by a trainee), comorbidities (SAS, COPD, and cardiac disease), examination time, total propofol dosage, and adverse events.</p><p>Only the BMI (<italic toggle="yes">p</italic> = 0.049) was a significant risk factor for delayed recovery time (Table&#x000a0;<xref rid="deo270025-tbl-0006" ref-type="table">6</xref>).</p><table-wrap position="float" id="deo270025-tbl-0006" content-type="TABLE"><label>TABLE 6</label><caption><p>Comparison of clinical characteristics&#x000a0;of delayed recovery time&#x000a0;on observational endoscopic ultrasonography.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">
<p>Total</p>
<p>
<italic toggle="yes">n</italic> = 437</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Recovery time &#x0003c;30</p>
<p>
<italic toggle="yes">n</italic> = 327</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Recovery time &#x02265;30</p>
<p>
<italic toggle="yes">n</italic> = 110</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median age, years (range)</td><td align="char" rowspan="1" colspan="1">64&#x000a0;(28&#x02013;90)</td><td align="char" rowspan="1" colspan="1">63&#x000a0;(30&#x02013;90)</td><td align="char" rowspan="1" colspan="1">65&#x000a0;(30&#x02013;89)</td><td align="char" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">219 (50.1)</td><td align="char" rowspan="1" colspan="1">169&#x000a0;(51.6)</td><td align="char" rowspan="1" colspan="1">50&#x000a0;(45.5)</td><td align="char" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Median&#x000a0;BMI,&#x000a0;kg/m<sup>2</sup>&#x000a0;(range)</td><td align="char" rowspan="1" colspan="1">22.4 (14.0&#x02013;38.1)</td><td align="char" rowspan="1" colspan="1">22.6 (14.0&#x02013;38.1)</td><td align="char" rowspan="1" colspan="1">22.0 (14.0&#x02013;31.2)</td><td align="char" rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" rowspan="1" colspan="1">Simultaneous performance of&#x000a0;EGD, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">88&#x000a0;(20.1)</td><td align="char" rowspan="1" colspan="1">61&#x000a0;(18.7)</td><td align="char" rowspan="1" colspan="1">27&#x000a0;(24.5)</td><td align="char" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">EUS provider, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Trainee + trainer</td><td align="char" rowspan="1" colspan="1">286 (65.4)</td><td align="char" rowspan="1" colspan="1">213&#x000a0;(65.1)</td><td align="char" rowspan="1" colspan="1">73&#x000a0;(66.4)</td><td align="char" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">32&#x000a0;(7.3)</td><td align="char" rowspan="1" colspan="1">21&#x000a0;(6.4)</td><td align="char" rowspan="1" colspan="1">11&#x000a0;(10.0)</td><td align="char" rowspan="1" colspan="1">0.21</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">SAS</td><td align="char" rowspan="1" colspan="1">1 (0.2)</td><td align="char" rowspan="1" colspan="1">1&#x000a0;(0.3)</td><td align="char" rowspan="1" colspan="1">0&#x000a0;(0)</td><td align="char" rowspan="1" colspan="1">0.56</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">COPD</td><td align="char" rowspan="1" colspan="1">1&#x000a0;(0.2)</td><td align="char" rowspan="1" colspan="1">0&#x000a0;(0)</td><td align="char" rowspan="1" colspan="1">1&#x000a0;(0.9)</td><td align="char" rowspan="1" colspan="1">1.00</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cardiac disease</td><td align="char" rowspan="1" colspan="1">31&#x000a0;(7.1)</td><td align="char" rowspan="1" colspan="1">21&#x000a0;(6.4)</td><td align="char" rowspan="1" colspan="1">10&#x000a0;(9.1)</td><td align="char" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Median&#x000a0;examination&#x000a0;time,&#x000a0;min (range)</td><td align="char" rowspan="1" colspan="1">21&#x000a0;(10&#x02013;67)</td><td align="char" rowspan="1" colspan="1">21&#x000a0;(10&#x02013;67)</td><td align="char" rowspan="1" colspan="1">22&#x000a0;(10&#x02013;51)</td><td align="char" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">Median total propofol dose,&#x000a0;mg (range)</td><td align="char" rowspan="1" colspan="1">180 (60&#x02013;490)</td><td align="char" rowspan="1" colspan="1">180&#x000a0;(60&#x02013;490)</td><td align="char" rowspan="1" colspan="1">180&#x000a0;(80&#x02013;450)</td><td align="char" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">51&#x000a0;(11.7)</td><td align="char" rowspan="1" colspan="1">36&#x000a0;(11.0)</td><td align="char" rowspan="1" colspan="1">15&#x000a0;(13.6)</td><td align="char" rowspan="1" colspan="1">0.46</td></tr></tbody></table><table-wrap-foot><fn id="deo270025-tbl6-note-0001"><p>Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; EGDS, esophagogastroduodenoscopy; EUS, endoscopic ultrasonography;&#x000a0;SAS, sleep apnea syndrome.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>In addition, univariate and multivariate analyses were performed for age (&#x0003e;65 years, &#x02264;65 years), sex, BMI (&#x0003e;25 kg/m<sup>2</sup>, &#x02264;25 kg/m<sup>2</sup>), whether EGD was performed simultaneously, adverse events, comorbidities, examination time (&#x0003e;22 min, &#x02264;22 min), and total propofol dose (&#x02265;180 mg, &#x0003c;180 mg; Table&#x000a0;<xref rid="deo270025-tbl-0007" ref-type="table">7</xref>). The groups were divided based on the median age, examination time, and propofol dose. In univariate analysis, high BMI (OR 1.72 [95% CI: 1.05&#x02013;2.82, <italic toggle="yes">p</italic> = 0.03]), simultaneous performance of EGD (OR 1.74 [95% CI: 1.07&#x02013;2.82, <italic toggle="yes">p</italic> = 0.03]), long examination time (&#x0003e;22 min; OR 1.64 [95% CI: 1.05&#x02013;2.56, <italic toggle="yes">p</italic> = 0.03]) were risk factors for delayed recovery. In multivariate analysis, high BMI (OR 1.87 [95% CI: 1.10&#x02013;3.16, <italic toggle="yes">p</italic> = 0.02]), simultaneous performance of EGD (OR 1.68 [95% CI: 0.97&#x02013;2.92, <italic toggle="yes">p</italic> = 0.06]), long examination time (&#x0003e;22 min; OR 4.23 [95% CI: 2.08&#x02013;8. 57, <italic toggle="yes">p</italic> &#x0003c; 0.001]), indicating that a high BMI and long examination time were risk factors for delayed recovery.</p><table-wrap position="float" id="deo270025-tbl-0007" content-type="TABLE"><label>TABLE 7</label><caption><p>Factors affecting&#x000a0;delayed&#x000a0;recovery time&#x000a0;in observational&#x000a0;endoscopic ultrasonography.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">Univariate analysis</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">Multivariate analysis</th></tr><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="left" rowspan="1" colspan="1">Recovery time&#x000a0;&#x02265;30&#x000a0;(%)</th><th align="left" rowspan="1" colspan="1">
<bold>OR</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">p</italic>&#x02010;value</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>OR</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">p</italic>&#x02010;value</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003c;65</td><td align="left" rowspan="1" colspan="1">229</td><td align="left" rowspan="1" colspan="1">21.4&#x000a0;(49/229)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x02265;65</td><td align="left" rowspan="1" colspan="1">208</td><td align="left" rowspan="1" colspan="1">29.3&#x000a0;(61/208)</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">0.7&#x02013;1.67</td><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">218</td><td align="left" rowspan="1" colspan="1">23.9&#x000a0;(52/218)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">219</td><td align="left" rowspan="1" colspan="1">26.5&#x000a0;(58/219)</td><td align="left" rowspan="1" colspan="1">1.18</td><td align="left" rowspan="1" colspan="1">0.76&#x02013;1.82</td><td align="left" rowspan="1" colspan="1">0.46</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003c;25</td><td align="left" rowspan="1" colspan="1">339</td><td align="left" rowspan="1" colspan="1">23.0&#x000a0;(78/339)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x02265;25</td><td align="left" rowspan="1" colspan="1">98</td><td align="left" rowspan="1" colspan="1">32.7&#x000a0;(32/98)</td><td align="left" rowspan="1" colspan="1">1.72</td><td align="left" rowspan="1" colspan="1">1.05&#x02013;2.82</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">1.87</td><td align="left" rowspan="1" colspan="1">1.10&#x02013;3.16</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Simultaneous performance of&#x000a0;EGD</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">349</td><td align="left" rowspan="1" colspan="1">21.8&#x000a0;(76/349)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">88</td><td align="left" rowspan="1" colspan="1">38.6&#x000a0;(34/88)</td><td align="left" rowspan="1" colspan="1">1.74</td><td align="left" rowspan="1" colspan="1">1.07&#x02013;2.82</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">1.68</td><td align="left" rowspan="1" colspan="1">0.97&#x02013;2.92</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse&#x000a0;events</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">13.7&#x000a0;(7/51)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">386</td><td align="left" rowspan="1" colspan="1">26.6&#x000a0;(103/386)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1.47</td><td align="left" rowspan="1" colspan="1">0.71&#x02013;3.05</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">405</td><td align="left" rowspan="1" colspan="1">23.5&#x000a0;(95/405)&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">46.9&#x000a0;(15/32)</td><td align="left" rowspan="1" colspan="1">1.99</td><td align="left" rowspan="1" colspan="1">1.00&#x02013;3.94</td><td align="left" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Examination time (min)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003c;22</td><td align="left" rowspan="1" colspan="1">228</td><td align="left" rowspan="1" colspan="1">9.6&#x000a0;(22/228)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x02265;22</td><td align="left" rowspan="1" colspan="1">209</td><td align="left" rowspan="1" colspan="1">17.7&#x000a0;(37/209)</td><td align="left" rowspan="1" colspan="1">1.64</td><td align="left" rowspan="1" colspan="1">1.05&#x02013;2.56</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">4.23</td><td align="left" rowspan="1" colspan="1">2.08&#x02013;8.57</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total propofol dose (mg)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x0003e;180</td><td align="left" rowspan="1" colspan="1">216</td><td align="left" rowspan="1" colspan="1">16.7&#x000a0;(36/216)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">&#x02264;180</td><td align="left" rowspan="1" colspan="1">221</td><td align="left" rowspan="1" colspan="1">10.4&#x000a0;(23/221)</td><td align="left" rowspan="1" colspan="1">1.24</td><td align="left" rowspan="1" colspan="1">0.80&#x02013;1.93</td><td align="left" rowspan="1" colspan="1">0.34</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr></tbody></table><table-wrap-foot><fn id="deo270025-tbl7-note-0001"><p>Abbreviations: BMI, body mass index; COPD, chronic obstructive&#x000a0;pulmonary disease; EGDS, esophagogastroduodenoscopy; SAS, sleep apnea syndrome.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="deo270025-sec-0180"><title>DISCUSSION</title><p>In this study, we found that using propofol alone for observational biliopancreatic EUS led to increased patient satisfaction, fewer adverse events, and quicker recovery time post&#x02010;examination before discharge.</p><p>Liang et&#x000a0;al. compared propofol&#x02010;dexmedetomidine and propofol&#x02010;remifentanil during EUS examination and reported mean total doses of 233 and 244 mg, respectively.<xref rid="deo270025-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Okamoto et&#x000a0;al. reported a median total dose of 159 mg for propofol sedation during biliopancreatic EUS using a Bispectral Index (BIS) monitor without mention of concomitant analgesia.<xref rid="deo270025-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> The median total propofol dose at our hospital was 186.5 mg, and there was no significant difference in total propofol dose between analgesic use and no analgesic use compared to previous reports.</p><p>Regarding examination time and patient satisfaction, Liang et&#x000a0;al. reported a mean time of 27.3 min and a mean VAS score of 0.12.<xref rid="deo270025-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> In this study, the median examination time was 22 min, and although there was a difference between the mean and median, the examination time did not differ significantly from that in previous reports of concomitant analgesia.</p><p>Furthermore, the median VAS score was 0, indicating high patient satisfaction with or without the use of analgesics. The previous study did not mention the performing physician; however, this present study showed no significant difference in VAS scores and a high level of satisfaction, even if the performing physician was a trainee.</p><p>Liang et&#x000a0;al. and Okamoto et&#x000a0;al. reported adverse events in 10.2% and 17.3% of patients, respectively.<xref rid="deo270025-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="deo270025-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Yusoff et&#x000a0;al. reported mild hypoxemia in 20% of cases but no cases of severe hypoxemia (saturation &#x0003c;85%).<xref rid="deo270025-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> In this study, the rate of adverse events was 11.6%, which could be improved through appropriate monitoring.</p><p>Regarding the risk of adverse events, a significant difference was observed in the risk of adverse events due to COPD comorbidity; however, the number of patients was only 3, and further studies are warranted, including more cases. Moreover, a significant difference was observed in examinations conducted solely by trainees. This is assumed to be because of their tendency to cause patient movement through excessive endoscopic maneuvering. As a result, localized propofol administration may be necessary, leading to potential adverse events. Trainers should appropriately control the examination time and endoscopic maneuvering of the trainees.</p><p>In outpatients, Liang et&#x000a0;al. reported a mean time of 16.56 &#x000b1; 3.91 and 15.39 &#x000b1; 3.8 min from the end of the examination to the release from rest for the propofol&#x02010;dexmedetomidine and propofil&#x02010;remifentanil groups, respectively.<xref rid="deo270025-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Okamoto et&#x000a0;al. also reported that propofol sedation during EUS examinations using a BIS monitor resulted in a recovery time of 22.5 min.<xref rid="deo270025-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Despite the difference in the method used to evaluate the exit criteria, the median recovery time in this study was 22 min and no differences were found.</p><p>Significant differences were found between high BMI and long examination times as risk factors for delayed recovery time. This may be because obesity can affect propofol blood concentration, making it challenging to adjust the effective threshold at high BMI. Drug doses may also be excessive based on total body weight.<xref rid="deo270025-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270025-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>In addition, acute pancreatitis was observed in one patient (0.002%) as a post&#x02010;examination adverse event. In this case, no stressful endoscopic manipulation, such as balloon dilation at the papillary site, was performed. Therefore, we considered this case to be drug&#x02010;induced pancreatitis caused by propofol. The clinical course of the patient improved quickly after fasting and supplemental fluid therapy alone.</p><p>Notably, several case reports have indicated an association between propofol and pancreatitis.<xref rid="deo270025-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="deo270025-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The exact mechanisms are still unclear, but proposed causes include hypertriglyceridemia, hypersensitivity, and direct pancreatic toxicity of the drug.<xref rid="deo270025-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> It is essential to consider acute pancreatitis as an adverse event of propofol.</p><p>In surgery, sedation involves using a combination of drugs with varying mechanisms of action to minimize individual side effects.<xref rid="deo270025-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="deo270025-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> However, in this study, sedation with propofol alone in observational EUS showed no difference in patient satisfaction, adverse events, or patient recovery time compared with previous reports.</p><p>This study has limitations as it was a single&#x02010;center, retrospective study without a comparison of analgesic combinations and used a biased echoendoscope. Therefore, a multicenter, prospective comparative study with a combined analgesic group is recommended to eliminate bias from the echoendoscope.</p><p>Trainers should appropriately control the examination time and endoscopic maneuvering of the trainees. However, the number of additional doses was not examined in this study, and a comparison of the number of local doses by the trainee and trainer is considered necessary in the future.</p><p>In conclusion, propofol alone is an effective sedation method for observational biliopancreatic EUS, resulting in high patient satisfaction and overall safety.</p></sec><sec sec-type="COI-statement" id="deo270025-sec-0190"><title>CONFLICT OF INTEREST STATEMENT</title><p>Haruhiro Inoue, who received grants from the Olympus Corporation and Takeda Pharmaceutical Company, is an advisor for Olympus Corporation and Top Corporation. The other authors declare no conflict of interest.</p></sec><sec id="deo270025-sec-0200"><title>ETHICS STATEMENT</title><p>The Showa University Koto Toyosu Hospital Review Board (No. 2023&#x02010;229&#x02010;B) approved this study. This study conformed to the provisions of the Declaration of Helsinki (revised in Fortaleza, Brazil, October 2013).</p></sec><sec id="deo270025-sec-0210"><title>PATIENT INFORMED CONSENT</title><p>With approval from the Showa University Koto Toyosu Hospital Review Board (No. 2023&#x02010;229&#x02010;B), informed consent was obtained through an opt&#x02010;out method. In this method, instead of obtaining written consent from each individual, the research content was disclosed on a web homepage, and the opportunity to refuse participation in the research was provided.&#x000a0;&#x000a0;</p></sec></body><back><ref-list id="deo270025-bibl-0001"><title>REFERENCES</title><ref id="deo270025-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270025-cit-0001">
<string-name>
<surname>Cohen</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Ladas</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Vargo</surname>
<given-names>JJ</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Sedation in digestive endoscopy: The Athens international position statements</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2010</year>; <volume>32</volume>: <fpage>425</fpage>&#x02013;<lpage>442</lpage>.<pub-id pub-id-type="pmid">20456310</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270025-cit-0002">
<string-name>
<surname>Cohen</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Delegge</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Aisenberg</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>AGA Institute review of endoscopic sedation</article-title>. <source>Gastroenterology</source>
<year>2007</year>; <volume>133</volume>: <fpage>675</fpage>&#x02013;<lpage>701</lpage>.<pub-id pub-id-type="pmid">17681185</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270025-cit-0003">
<string-name>
<surname>Dietrich</surname>
<given-names>CF</given-names>
</string-name>. <article-title>Endosonography as theme of this issue&#x02013;Update of endoscopic ultrasound techniques</article-title>. <source>Z Gastroenterol</source>
<year>2008</year>; <volume>46</volume>: <fpage>553</fpage>&#x02013;<lpage>554</lpage>
<pub-id pub-id-type="pmid">18537082</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270025-cit-0004">
<string-name>
<surname>Dumonceau</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Riphaus</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schreiber</surname>
<given-names>F</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Non&#x02010;anesthesiologist administration of propofol for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates Guideline&#x02015;Updated June 2015</article-title>. <source>Endoscopy</source>
<year>2015</year>; <volume>47</volume>: <fpage>1175</fpage>&#x02013;<lpage>1189</lpage>.<pub-id pub-id-type="pmid">26561915</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270025-cit-0005">
<string-name>
<surname>Uksel</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Parlak</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Koklu</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Conscious sedation during endoscopic retrograde cholangiopancreatography: Midazolam or midazolam plus meperidine?</article-title>
<source>Eur J Gastroenterol Hepatol</source>
<year>2007</year>; <volume>19</volume>: <fpage>1002</fpage>&#x02013;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">18049171</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270025-cit-0006">
<string-name>
<surname>Sethi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wadhwa</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Thaker</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Propofol versus traditional sedative agents for advanced endoscopic procedures: Meta&#x02010;analysis</article-title>. <source>Dig Endosc</source>
<year>2014</year>; <volume>26</volume>: <fpage>515</fpage>&#x02013;<lpage>524</lpage>.<pub-id pub-id-type="pmid">24354404</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270025-cit-0007">
<string-name>
<surname>Danny</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Michael</surname>
<given-names>FB</given-names>
</string-name>. <article-title>Propofol use in endoscopic retrograde cholangiopancreatography and endoscopic ultrasound</article-title>. <source>World J Gastroenterol</source>
<year>2014</year>; <volume>20</volume>: <fpage>5171</fpage>&#x02013;<lpage>5176</lpage>
<pub-id pub-id-type="pmid">24833847</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270025-cit-0008">
<string-name>
<surname>Yusoff</surname>
<given-names>IF</given-names>
</string-name>, <string-name>
<surname>Raymond</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sahai</surname>
<given-names>AV</given-names>
</string-name>. <article-title>Endoscopist administered propofol for upper&#x02010;GI EUS is safe and effective: A prospective study in 500 patients</article-title>. <source>Gastrointest Endosc</source>
<year>2004</year>; <volume>60</volume>: <fpage>356</fpage>&#x02013;<lpage>360</lpage>.<pub-id pub-id-type="pmid">15332023</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo270025-cit-0009">
<string-name>
<surname>Cheriyan</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Byrne</surname>
<given-names>MF</given-names>
</string-name>. <article-title>Propofol use in endoscopic retrograde cholangiopancreatography and endoscopic ultrasound</article-title>. <source>World J Gastroenterol</source>
<year>2014</year>; <volume>20</volume>: <fpage>5171</fpage>&#x02013;<lpage>5176</lpage>.<pub-id pub-id-type="pmid">24833847</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo270025-cit-0010">
<string-name>
<surname>Zhao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>. <article-title>Comparison effects of propofol&#x02010;dexmedetomidine versus propofol&#x02010;remifentanil for endoscopic ultrasonography: A prospective randomized comparative trial</article-title>. <source>Biomed Res Int</source>
<year>2022</year>; <volume>2022</volume>: <elocation-id>3305696</elocation-id>.<pub-id pub-id-type="pmid">36389109</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo270025-cit-0011">
<string-name>
<surname>Sessler</surname>
<given-names>CN</given-names>
</string-name>, <string-name>
<surname>Gosnell</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Grap</surname>
<given-names>MJ</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The Richmond Agitation&#x02010;Sedation Scale</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2002</year>; <volume>166</volume>: <fpage>1338</fpage>&#x02013;<lpage>1344</lpage>.<pub-id pub-id-type="pmid">12421743</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270025-cit-0012">
<string-name>
<surname>Ely</surname>
<given-names>EW</given-names>
</string-name>, <string-name>
<surname>Truman</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Shintani</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Monitoring sedation status over time in ICU patients: Reliability and validity of the Richmond Agitation&#x02010;Sedation Scale (RASS)</article-title>. <source>JAMA</source>
<year>2003</year>; <volume>289</volume>: <fpage>2983</fpage>&#x02013;<lpage>2991</lpage>.<pub-id pub-id-type="pmid">12799407</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270025-cit-0013">
<string-name>
<surname>Aldrete</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Kroulik</surname>
<given-names>D</given-names>
</string-name>. <article-title>A postanesthetic recovery score</article-title>. <source>Anesth Analg</source>
<year>1970</year>; <volume>49</volume>: <fpage>924</fpage>&#x02013;<lpage>934</lpage>.<pub-id pub-id-type="pmid">5534693</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270025-cit-0014">
<string-name>
<surname>Lovett</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>G&#x000f3;mez</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Hodge</surname>
<given-names>DO</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Propofol versus midazolam/fentanyl sedation for colonoscopy in the elderly patient population</article-title>. <source>J Perianesth Nurs</source>
<year>2017</year>; <volume>32</volume>: <fpage>210</fpage>&#x02013;<lpage>214</lpage>.<pub-id pub-id-type="pmid">28527548</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270025-cit-0015">
<string-name>
<surname>Schmitz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kellenberger</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Sedation for magnetic resonance imaging using propofol with or without ketamine at induction in pediatrics: A prospective randomized double&#x02010;blinded study</article-title>. <source>Paediatr Anaesth</source>
<year>2018</year>; <volume>28</volume>: <fpage>264</fpage>&#x02013;<lpage>274</lpage>.<pub-id pub-id-type="pmid">29377404</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo270025-cit-0016">
<string-name>
<surname>Cotton</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Eisen</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Aabakken</surname>
<given-names>L</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>A lexicon for endoscopic adverse events: Report of an ASGE workshop</article-title>. <source>Gastrointest Endosc</source>
<year>2010</year>; <volume>71</volume>: <fpage>446</fpage>&#x02013;<lpage>454</lpage>.<pub-id pub-id-type="pmid">20189503</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo270025-cit-0017">
<string-name>
<surname>Okamoto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kamata</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miyata</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Bispectral index&#x02010;guided propofol sedation during endoscopic ultrasonography</article-title>. <source>Clin Endosc</source>
<year>2022</year>; <volume>55</volume>: <fpage>558</fpage>&#x02013;<lpage>563</lpage>.<pub-id pub-id-type="pmid">35817564</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo270025-cit-0018">
<string-name>
<surname>Kim</surname>
<given-names>TK</given-names>
</string-name>. <article-title>Obesity and anesthetic pharmacology: Simulation of target&#x02010;controlled infusion models of propofol and remifentanil</article-title>. <source>Korean J Anesthesiol</source>
<year>2021</year>; <volume>74</volume>: <fpage>478</fpage>&#x02013;<lpage>487</lpage>.<pub-id pub-id-type="pmid">34407372</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo270025-cit-0019">
<string-name>
<surname>Smith</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Coetzee</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Jurgens</surname>
<given-names>FX</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>An observational study is the induction of anesthesia with propofol according to the adjusted ideal body mass in obese and non&#x02010;obese patients</article-title>. <source>South Afr J Anaesth Analg</source>
<year>2019</year>; <volume>25</volume>: <fpage>6</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="deo270025-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo270025-cit-0020">
<string-name>
<surname>Samir</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ravinder</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Sushil</surname>
<given-names>KG</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Acute pancreatitis associated with intravenous administration of propofol: Evaluation of causality in a systematic review of the literature</article-title>. <source>Gastroenterology Rep</source>
<year>2019</year>; <volume>7</volume>: <fpage>13</fpage>&#x02013;<lpage>23</lpage>.</mixed-citation></ref><ref id="deo270025-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo270025-cit-0021">
<string-name>
<surname>Akarsh</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Howard</surname>
<given-names>Z</given-names>
</string-name>. <article-title>Propofol&#x02010;induced severe necrotizing pancreatitis</article-title>. <source>ACG Case Rep J</source>
<year>2021</year>; <volume>8</volume>: <elocation-id>e00528</elocation-id>.<pub-id pub-id-type="pmid">33490299</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="deo270025-cit-0022">
<string-name>
<surname>Asghar</surname>
<given-names>MU</given-names>
</string-name>, <string-name>
<surname>Cheema</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Tanveer</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Leinwand</surname>
<given-names>J</given-names>
</string-name>. <article-title>Propofol infusion and acute pancreatitis: A review</article-title>. <source>Am J Ther</source>
<year>2020</year>; <volume>27</volume>: <fpage>e371</fpage>&#x02013;<lpage>374</lpage>.<pub-id pub-id-type="pmid">31283535</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="deo270025-cit-0023">
<string-name>
<surname>Christine</surname>
<given-names>SML</given-names>
</string-name>, <string-name>
<surname>Ronald</surname>
<given-names>SC</given-names>
</string-name>. <article-title>Enhanced recovery after surgery programs improve patient outcomes and recovery: A meta&#x02010;analysis</article-title>. <source>World J Surg</source>
<year>2017</year>; <volume>41</volume>: <fpage>899</fpage>&#x02013;<lpage>913</lpage>
<pub-id pub-id-type="pmid">27822725</pub-id>
</mixed-citation></ref><ref id="deo270025-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="deo270025-cit-0024">
<string-name>
<surname>Henrik</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Douglas</surname>
<given-names>WW</given-names>
</string-name>. <article-title>Multimodal strategies to improve surgical outcome</article-title>. <source>Am J Surg</source>
<year>2002</year>; <volume>183</volume>: <fpage>630</fpage>&#x02013;<lpage>641</lpage>.<pub-id pub-id-type="pmid">12095591</pub-id>
</mixed-citation></ref></ref-list></back></article>